Severe Hypertriglyceridemia Emerging and Marketed Drugs Assessment, (2023 Updates) | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

 Breaking News
  • No posts were found

Severe Hypertriglyceridemia Emerging and Marketed Drugs Assessment, (2023 Updates) | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

March 13
22:16 2023
Severe Hypertriglyceridemia Emerging and Marketed Drugs Assessment, (2023 Updates) | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, about 10+ key pharma and biotech companies are working on 10+ pipeline drugs in the Severe Hypertriglyceridemia (SHTG) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

As per DelveInsight, the Severe Hypertriglyceridemia therapeutics market is anticipated to increase in the coming years owing to the rise in the prevalence of the disorder, backed by various pipeline products in the late stages of development. The patient population is expected to increase due to the triple epidemic of obesity, metabolic syndrome, and Type 2 diabetes. While existing therapies may decrease triglyceride levels, they generally do not have broader metabolic benefits, underscoring the urgent need for additional therapeutic options.

Major players such as Pfizer, Regeneron Pharmaceuticals, Acasti Pharma, Arrowhead Pharmaceuticals, Inc., etc., are developing various therapies for the SHTG. The expected launch of emerging therapies such as Evinacumab, ARO-APOC3, and others are anticipated to improve the Severe Hypertriglyceridemia treatment scenario in the coming years.

Severe Hypertriglyceridemia (SHTG) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Severe Hypertriglyceridemia Market. 

The Severe Hypertriglyceridemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Severe Hypertriglyceridemia Pipeline Analysis

Severe Hypertriglyceridemia Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Severe Hypertriglyceridemia and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Severe Hypertriglyceridemia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates


Route of Administration

Severe Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Inhalation

  • Inhalation/Intravenous/Oral

  • Intranasal

  • Intravenous

  • Intravenous/ Subcutaneous

  • Oral

  • Oral/intranasal/subcutaneous

  • Parenteral

  • Subcutaneous


Molecule Type

Products have been categorized under various Molecule types, such as

  • Antibody

  • Antisense oligonucleotides

  • Immunotherapy

  • Monoclonal antibody

  • Peptides

  • Protein

  • Recombinant protein

  • Small molecule

  • Stem Cell

  • Vaccine

Learn How the Ongoing Clinical & Commercial Activities will Affect the Severe Hypertriglyceridemia Therapeutic Segment @

Severe Hypertriglyceridemia Therapeutics Landscape

Current treatments generally seem to provide modest reductions in triglycerides, and many people remain uncontrolled and at risk of developing pancreatitis. Thus, there remains a significant need for new therapies that can substantially lower triglycerides in the bloodstream to help further minimize the impact of this serious Condition.

To improve the treatment scenario, about 10+ key companies are developing therapies for Severe Hypertriglyceridemia. Currently,  Ionis Pharmaceuticals is leading the therapeutics market with its Severe Hypertriglyceridemia drug candidates in the most advanced stage of clinical development.

Leading Companies in the Severe Hypertriglyceridemia (SHTG) Therapeutics Market Include:

  • 89bio, Inc

  • Acasti Pharma Inc.

  • Amarin Corporation

  • Arrowhead

  • Ionis Pharmaceuticals

  • Kowa Research Institute, Inc.

  • Matinas BioPharma

  • Mochida Pharmaceutical

  • NorthSea Therapeutics B.V.

  • Pfizer

  • Regeneron

  • Regeneron Pharmaceuticals

And Many Others

Severe Hypertriglyceridemia Emerging and Marketed Drugs Covered in the Report Include:

  • ARO-APOC3: Arrowhead

  • Evinacumab: Regeneron

  • Olezarsen: Ionis Pharmaceuticals

  • SEFA-1024: NorthSea Therapeutics

  • VASCEPA/VAZKEPA: Amarin Corporation

  • Vupanorsen: Pfizer

And many more


Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Severe Hypertriglyceridemia Current Treatment Patterns

4. Severe Hypertriglyceridemia – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Severe Hypertriglyceridemia Late Stage Products (Phase-III)

7. Severe Hypertriglyceridemia Mid-Stage Products (Phase-II)

8. Severe Hypertriglyceridemia Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Severe Hypertriglyceridemia Discontinued Products

13. Severe Hypertriglyceridemia Product Profiles

14. Key Companies in the Severe Hypertriglyceridemia Market

15. Key Products in the Severe Hypertriglyceridemia Therapeutics Segment

16. Dormant and Discontinued Products

17. Severe Hypertriglyceridemia Unmet Needs

18. Severe Hypertriglyceridemia Future Perspectives

19. Severe Hypertriglyceridemia Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Related Articles